Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
Epithelioid malignant pleural mesothelioma (MPM) can easily be confused with lung adenocarcinomas (ACAs). In serous effusion, claudin (cldn) 3 is shown to be useful in the diagnosis of mesothelioma vs ACAs. Cldn15 is reported to be overexpressed in epithelioid mesothelioma and absent in human airway epithelium. The aim was to assess the value of cldn3 and cldn4 compared to that of BerEp4 and thyroid transcription factor-1 (TTF1) in differentiating lung ACA from epithelioid MPM and to examine the expression of cldn15 in these tumors. The expression of cldn3, cldn4, cldn15, BerEp4, and TTF1 was examined by immunohistochemistry in a total of 62 human specimen including 28 epithelioid MPMs and 34 ACAs of the lung. In lung ACA, cldn4 was strongly expressed in all 34 (100%) specimens followed by cldn3 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. TTF1 reacted for only 20 (58.82%) of 34 cases of lung ACA. In MPM specimens, the expression of cldn3 and4 as well as that of TTF1 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid MPM. Cldn15 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung ACAs. Its expression was moderate in normal pleura and limited in normal lung. Cldn3 and cldn4 appear to be the best performing carcinoma markers in discriminating lung ACA from mesothelioma compared with BerEp4 and TTF1. There is no differential expression of cldn15 between the 2 pathologies. However, the limited cldn15 expression in normal tissues and high expression in tumors make it an attractive candidate for cancer therapy.
Department of Biology, Kouba High School, Algiers, Algeria. Electronic address: mazouni@ens-kouba.dz.
Siham
S
Chaouche-Mazouni
Department of Pulmonary and Thoracic Oncology, Lille University Hospital, Lille, France.
Arnaud
A
Scherpereel
Department of Pneumophtysiology, Public Hospital of Rouiba, Algeria.
Rima
R
Zaamoum
Department of Pathology, Hospital of St Vincent, GHICL, Lille, France.
Adriana
A
Mihalache
Department of Pathology, Hospital of Mustapha Pacha, Algiers, Algeria.
Zine-Charaf
ZC
Amir
Department of Biology, Kouba High School, Algiers, Algeria.
Nemcha
N
Lebaïli
Department of Pathology, Hospital of St Vincent, GHICL, Lille, France.
Baptiste
B
Delaire
Department of Pathology, Hospital of St Vincent, GHICL, Lille, France.
Pierre
P
Gosset
D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000378:metabolism; D057167:Claudins / Q000096:biosynthesis*; D004268:DNA-Binding Proteins / Q000378:metabolism; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008654:Mesothelioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000086002:Mesothelioma, Malignant; D010997:Pleural Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D012680:Sensitivity and Specificity; D014157:Transcription Factors; D000951:Antigens, Neoplasm
D014408:Biomarkers, Tumor; D057167:Claudins; D004268:DNA-Binding Proteins; D014157:Transcription Factors; C504003:TTF1 protein, human; C115012:human epithelial antigen-125; D000951:Antigens, Neoplasm
Claudins; Diagnosis; Lung adenocarcinoma; Mesothelioma; Therapeutic target